BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Autosomal Dominant Polycystic Kidney Disease readouts · Asset
 Memo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Autosomal Dominant Po
 lycystic Kidney Disease\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07161037-10842@assetmemo.bio
DTSTAMP:20261121T005959Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:VX-407: Phase 2 readout est. (NCT07161037)
DESCRIPTION:VX-407\, phase 2\, Autosomal Dominant Polycystic Kidney Disease
 .\nStudy: Phase 2a Study of VX-407 in Participants With ADPKD Who Have a S
 ubset of PKD1 Gene Variants (AGLOW)\nEstimated primary completion: 22 July
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/vx-407#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07161037
URL:https://assetmemo.bio/drug/vx-407#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
